HER2 Breast Cancer

During an in-person Community Case Forum in partnership with the Rocky Mountain Oncology Society, Mei Wei, MD, discussed data from the TROPiCS-02 trial of sacituzumab govitecan in patients with metastatic breast cancer.

Analysis of the TROPION-Breast01 study showed that treatment with Dato-DXd did not significantly improve overall survival compared with chemotherapy in HR-positive, HER2-low or -negative breast cancer.

Following its initial approval at 150 mg, trastuzumab-strf has also been approved at 420 mg for the treatment of several HER2-overexpressing cancers.

The phase 2 BRACELET-1 trial demonstrated that the combination of pelareorep and paclitaxel significantly improved outcomes for patients with HR-positive/HER2-negative metastatic breast cancer.

Adjuvant ribociclib plus an aromatase inhibitor is now an FDA-approved treatment in HR-positive, HER2-negative stage II and III early breast cancer at a high risk of recurrence.

Combining endocrine therapy with the dual HER2 blockade of trastuzumab and pertuzumab and the CDK4/6 inhibitor ribociclib showed potential as a novel approach for patients with HR+/HER2+ breast cancer.

Patient-reported outcomes from DESTINY-Breast06 show trastuzumab deruxtecan improved time to deterioration for pain and other subscores, with no decline in overall QOL in either arm in the HER2 low/ultralow breast cancer setting.

Neoadjuvant endocrine therapy followed by targeted therapy led to excellent survival outcomes in patients with hormone-receptor-positive, HER2-positive early breast cancer.

In a 10-year analysis of the ShortHER trial, high tumor-infiltrating lymphocytes were associated with improved survival in patients with early HER2-positive breast cancer treated with adjuvant chemotherapy and trastuzumab.

Naomi Dempsey, MD, discussed developments in the HER2-positive breast cancer space, including personalized approaches, less toxic treatments, promising trial results, and more.

HER2DX has shown a strong association between ERBB2 mRNA and survival in patients with HER2-positive breast cancer.

The breakthrough therapy designation is supported by findings from the phase 3 DESTINY-Breast06 study comparing the antibody-drug conjugate with chemotherapy in patients with HR+/HER2-low breast cancer.

The standard first-line treatment for patients with HER2-positive metastatic breast cancer is pertuzumab and trastuzumab, which are anti-HER2 antibodies, plus a taxane.

In an interview with Targeted Oncology, Sarah Sammons, MD, discussed an analysis of the DESTINY-Breast03 trial, highlighting the need for further research on trastuzumab deruxtecan in other breast cancer subtypes and solid tumors with brain metastases.

Trastuzumab-strf, a biosimilar of trastuzumab, has received FDA approval for treating HER2-overexpressing breast cancer and metastatic gastric cancer.

Yara Abdou, MD, looks back on what have been the biggest challenges in treating HER2-positive breast cancer over the past 5-10 years.

The DESTINY-PanTumor02 trial and the HERALD/EPOC1806 study are showing promising data regarding trastuzumab deruxtecan across several tumor types, including endometrial, cervical, ovarian, bladder, biliary tract, pancreatic, and more.

Rebecca A. Shatsky, MD, discusses the advantages of giving patients with HER2-positive breast cancer a subcutaneous injection of targeted therapy compared with the intravenous formulation of trastuzumab and pertuzumab.

Hatem Soliman, MD, highlights the crucial role of HER2 targeting and staying informed about evolving treatment options for better patient outcomes in the HER2-positive breast cancer space.

In an interview with Targeted Oncology, Reshma Mahtani, DO, discussed findings from a retrospective study exploring treatment options for geriatric patients with HER2-positive breast cancer.

In an interview with Targeted Oncology, Reshma Mahtani, DO, discussed findings of a quality improvement initiative identifying challenges for health care professionals and patients with HER2-positive breast cancer.

Rebecca A. Shatsky, MD, discusses the outcomes of the phase 3 FeDeriCa study of subcutaneous trastuzumab and pertuzumab in patients with HER2-positive breast cancer.

Hatem Soliman, MD, discusses what unmet needs still have to be addressed in the HER2-positive breast cancer space.

In the second article of a 2-part series, Yara Abdou, MD, provided a deep dive into the evolving landscape of HER2-targeted therapy and its potential to revolutionize cancer treatment.

In the first article of a 2-part series, Yara Abdou, MD, discussed the most significant challenges and transformative advancements in the treatment of HER2-positive breast cancer.

In an interview with Targeted Oncology, Reshma Mahtani, DO, discussed data from a quality improvement initiative identifying issues for health care professionals and patients with HER2-positive breast cancer.

Treatment with trastuzumab maintains its place as the backbone of therapy in the first-line setting for management of patients with HER2-positive metastatic breast cancer.

Trastuzumab deruxtecan emerges as a superior second-line option for HER2-positive metastatic breast cancer, with a fourfold increase in median progression-free survival vs trastuzumab emtansine, as reported in the DESTINY-Breast03 trial.